11/13
12:53 pm
indp
Indaptus Therapeutics, Inc. (NASDAQ: INDP) had its price target lowered by analysts at Maxim Group from $8.00 to $5.00. They now have a "buy" rating on the stock.
Low
Report
Indaptus Therapeutics, Inc. (NASDAQ: INDP) had its price target lowered by analysts at Maxim Group from $8.00 to $5.00. They now have a "buy" rating on the stock.
11/12
08:00 am
indp
Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Medium
Report
Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/11
08:00 am
indp
Indaptus Therapeutics’ Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology
Low
Report
Indaptus Therapeutics’ Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology
11/7
08:00 am
indp
Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting
Low
Report
Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting
10/23
08:00 am
indp
Indaptus Therapeutics to Present at Two Upcoming Investor Conferences
Medium
Report
Indaptus Therapeutics to Present at Two Upcoming Investor Conferences
10/22
08:00 am
indp
Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations
High
Report
Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations
10/16
08:31 am
indp
Indaptus Therapeutics, Inc. (NASDAQ: INDP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Medium
Report
Indaptus Therapeutics, Inc. (NASDAQ: INDP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
10/15
08:00 am
indp
Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data
High
Report
Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data
10/10
08:00 am
indp
Indaptus Therapeutics Founder and Chief Scientific Officer to Speak on Lumanity Webinar about the Future of Innate Immunity in Cancer Immunotherapy
High
Report
Indaptus Therapeutics Founder and Chief Scientific Officer to Speak on Lumanity Webinar about the Future of Innate Immunity in Cancer Immunotherapy
10/8
08:00 am
indp
Indaptus Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
Medium
Report
Indaptus Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
9/5
08:30 am
indp
Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses
Low
Report
Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses
9/3
08:00 am
indp
Indaptus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Medium
Report
Indaptus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference